Natural gypenosides: targeting cancer through different molecular pathways

References

• Organization WH. Global health observatory data repository. Number of deaths (World) by cause: 2015; 2011.
   Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2129425651787
   PubMed Web of Science ®Google Scholar
• Bray F. Transitions in human development and the global cancer burden. World Cancer Rep. 2014;54–68.
   Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Qi F, Li A, Inagaki Y, et al. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends. 2010;4(6):297–307.21248427
   PubMed Web of Science ®Google Scholar
• Pereira DM, Valentao P, Correia-da-Silva G, Teixeira N, Andrade PB. Plant secondary metabolites in cancer chemotherapy: where are we? Curr Pharm Biotechnol. 2012;13(5):632–650. doi:10.2174/13892011279985753022122478
   PubMed Web of Science ®Google Scholar
• Coseri S. Natural products and their analogues as efficient anticancer drugs. Mini Rev Med Chem. 2009;9(5):560–571. doi:10.2174/13895570978816759219456286
   PubMed Web of Science ®Google Scholar
• Tascilar M, de Jong FA, Verweij J, Mathijssen RH. Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist. 2006;11(7):732–741. doi:10.1634/theoncologist.11-7-73216880232
   PubMed Web of Science ®Google Scholar
• Wang CZ, Calway T, Yuan CS. Herbal medicines as adjuvants for cancer therapeutics. Am J Chin Med. 2012;40(4):657–669. doi:10.1142/S0192415X1250049822809022
   PubMed Web of Science ®Google Scholar
• Committee NP. Pharmacopoeia of the People’s Republic of China. Part. 2010;1:392–393.
   Google Scholar
• Yin SY, Wei WC, Jian FY, Yang NS. Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med. 2013;2013:302426. doi:10.1155/2013/30242623956768
   PubMed Web of Science ®Google Scholar
• Kitano H. Systems biology: a brief overview. Science. 2002;295(5560):1662–1664. doi:10.1126/science.106949211872829
   PubMed Web of Science ®Google Scholar
• Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2012;81(4):303–311. doi:10.1111/j.1399-0004.2011.01809.x22082348
   PubMed Web of Science ®Google Scholar
• Li Y, Lin W, Huang J, Xie Y, Ma W. Anti-cancer effects of Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan). Chin Med. 2016;11:43. doi:10.1186/s13020-016-0114-927708693
   PubMed Web of Science ®Google Scholar
• Yang F, Shi H, Zhang X, Yu LL. Two novel anti-inflammatory 21-nordammarane saponins from tetraploid Jiaogulan (Gynostemma pentaphyllum). J Agric Food Chem. 2013;61(51):12646–12652. doi:10.1021/jf404726z24320209
   PubMed Web of Science ®Google Scholar
• Wu PK, Liu X, Hsiao WW-l. The assessment of anti-cancer activities and saponin profiles of Gynostemma pentaphyllum saponins obtained from different regions of China. J Biotechnol. 2008;136:S85. doi:10.1016/j.jbiotec.2008.07.192
   Web of Science ®Google Scholar
• Qian H, Fu S, Jiang G, Wang L, Fu X, Ye M. Protective effect of jiaogulan on cellular immunity of the patients with primary lung cancer treated by radiotherapy plus chemotherapy. Lung Cancer. 1996;1(14):156.
   Google Scholar
• Tai WC-S, Wong WY, Wang Y, Hsiao W-LW. The anti-cancer and anti-hyperlipidemia effects of triterpenoids from Gynostemma pentaphyllum in the Apc min/+ mouse model. AACR. 2010.
   Google Scholar
• Yang YH, Yang J, Jiang QH. Hypolipidemic effect of gypenosides in experimentally induced hypercholesterolemic rats. Lipids Health Dis. 2013;12:154. doi:10.1186/1476-511X-12-15424160562
   PubMed Web of Science ®Google Scholar
• Yu H, Guan Q, Guo L, et al. Gypenosides alleviate myocardial ischemia-reperfusion injury via attenuation of oxidative stress and preservation of mitochondrial function in rat heart. Cell Stress Chaperones. 2016;21(3):429–437. doi:10.1007/s12192-016-0705-526800973
   PubMed Web of Science ®Google Scholar
• Chen MH, Wang QF, Chen LG, et al. The inhibitory effect of Gynostemma pentaphyllum on MCP-1 and type I procollagen expression in rat hepatic stellate cells. J Ethnopharmacol. 2009;126(1):42–49. doi:10.1016/j.jep.2009.08.01219699789
   PubMed Web of Science ®Google Scholar
• Zhao J, Ming Y, Wan Q, et al. Gypenoside attenuates hepatic ischemia/reperfusion injury in mice via anti-oxidative and anti-apoptotic bioactivities. Exp Ther Med. 2014;7(5):1388–1392. doi:10.3892/etm.2014.156924940444
   PubMed Web of Science ®Google Scholar
• Tai WC, Wong WY, Lee MM, Chan BD, Lu C, Hsiao WL. Mechanistic study of the anti-cancer effect of Gynostemma pentaphyllum saponins in the Apc(Min/+) mouse model. Proteomics. 2016;16(10):1557–1569. doi:10.1002/pmic.20150029326970558
   PubMed Web of Science ®Google Scholar
• Yan H, Wang X, Niu J, Wang Y, Wang P, Liu Q. Anti-cancer effect and the underlying mechanisms of gypenosides on human colorectal cancer SW-480 cells. PLoS One. 2014;9(4):e95609. doi:10.1371/journal.pone.009560924752286
   PubMed Web of Science ®Google Scholar
• Yan H, Wang X, Wang Y, Wang P, Xiao Y. Antiproliferation and anti-migration induced by gypenosides in human colon cancer SW620 and esophageal cancer Eca-109 cells. Hum Exp Toxicol. 2014;33(5):522–533. doi:10.1177/096032711349330223900306
   PubMed Web of Science ®Google Scholar
• Lu KW, Chen JC, Lai TY, et al. Gypenosides inhibits migration and invasion of human oral cancer SAS cells through the inhibition of matrix metalloproteinase-2–9 and urokinase-plasminogen by ERK1/2 and NF-kappa B signaling pathways. Hum Exp Toxicol. 2011;30(5):406–415. doi:10.1177/096032711039652120511288
   PubMed Web of Science ®Google Scholar
• Chiu TH, Chen JC, Chung JG. N-acetyltransferase is involved in gypenosides-induced N-acetylation of 2-aminofluorene and DNA adduct formation in human cervix epidermoid carcinoma cells (Ca Ski). In Vivo. 2003;17(3):281–288.12929581
   PubMed Web of Science ®Google Scholar
• Zhao Y, Niu Y, Xie Z, Shi H, Chen P, Yu LL. Differentiating leaf and whole-plant samples of di-and tetraploid Gynostemma pentaphyllum (Thunb.) Makino using flow-injection mass spectrometric fingerprinting method. J Funct Foods. 2013;5(3):1288–1297. doi:10.1016/j.jff.2013.04.013
   Web of Science ®Google Scholar
• Jones DP. Redefining oxidative stress. Antioxid Redox Signal. 2006;8(9–10):1865–1879. doi:10.1089/ars.2006.8.186516987039
   PubMed Web of Science ®Google Scholar
• Mittler R, Vanderauwera S, Suzuki N, et al. ROS signaling: the new wave? Trends Plant Sci. 2011;16(6):300–309. doi:10.1016/j.tplants.2011.03.00721482172
   PubMed Web of Science ®Google Scholar
• Gloire G, Legrand-Poels S, Piette JN. F-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol. 2006;72(11):1493–1505. doi:10.1016/j.bcp.2006.04.01216723122
   PubMed Web of Science ®Google Scholar
• Gorlach A, Dimova EY, Petry A, et al. Reactive oxygen species, nutrition, hypoxia and diseases: problems solved? Redox Biol. 2015;6:372–385. doi:10.1016/j.redox.2015.08.01626339717
   PubMed Web of Science ®Google Scholar
• Gorlach A, Bertram K, Hudecova S, Krizanova O. Calcium and ROS: A mutual interplay. Redox Biol. 2015;6:260–271. doi:10.1016/j.redox.2015.08.01026296072
   PubMed Web of Science ®Google Scholar
• Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579–591. doi:10.1038/nrd299819478820
   PubMed Web of Science ®Google Scholar
• Hong YH, Uddin MH, Jo U, et al. ROS accumulation by PEITC selectively kills ovarian cancer cells via UPR-mediated apoptosis. Front Oncol. 2015;5:167. doi:10.3389/fonc.2015.0016726284193
   PubMed Web of Science ®Google Scholar
• Zhu L, Ren L, Chen Y, Fang J, Ge Z, Li X. Redox status of high-mobility group box 1 performs a dual role in angiogenesis of colorectal carcinoma. J Cell Mol Med. 2015;19(9):2128–2135. doi:10.1111/jcmm.1265826099505
   PubMed Web of Science ®Google Scholar
• Wei C, Xiao Q, Kuang X, Zhang T, Yang Z, Wang L. Fucoidan inhibits proliferation of the SKM-1 acute myeloid leukaemia cell line via the activation of apoptotic pathways and production of reactive oxygen species. Mol Med Rep. 2015;12(5):6649–6655. doi:10.3892/mmr.2015.425226324225
   PubMed Web of Science ®Google Scholar
• Seo KH, Ryu HW, Park MJ, et al. A furanoxanthone from garciana mangostana, induces reactive oxygen species-mediated apoptosis in lung cancer cells and decreases xenograft tumor growth. Phytother Res. 2015;29(11):1753–1760. doi:10.1002/ptr.542826310849
   PubMed Web of Science ®Google Scholar
• Kong L, Wang X, Zhang K, et al. Gypenosides synergistically enhances the anti-tumor effect of 5-fluorouracil on colorectal cancer in vitro and in vivo: a role for oxidative stress-mediated DNA damage and p53 activation. PLoS One. 2015;10(9):e0137888. doi:10.1371/journal.pone.013788826368019
   PubMed Web of Science ®Google Scholar
• Hsu HY, Yang JS, Lu KW, et al. An experimental study on the antileukemia effects of gypenosides in vitro and in vivo. Integr Cancer Ther. 2011;10(1):101–112. doi:10.1177/153473541037719820702487
   PubMed Web of Science ®Google Scholar
• Lin JJ, Hsu HY, Yang JS, et al. Molecular evidence of anti-leukemia activity of gypenosides on human myeloid leukemia HL-60 cells in vitro and in vivo using a HL-60 cells murine xenograft model. Phytomedicine. 2011;18(12):1075–1085. doi:10.1016/j.phymed.2011.03.00921596541
   PubMed Web of Science ®Google Scholar
• Liu J, Peng WX, Mo YY, Luo D. MALAT1-mediated tumorigenesis. Front Biosci (Landmark Ed). 2017;22:66–80. doi:10.2741/447227814602
   PubMed Web of Science ®Google Scholar
• Chen JC, Lu KW, Tsai ML, et al. Gypenosides induced G0/G1 arrest via CHk2 and apoptosis through endoplasmic reticulum stress and mitochondria-dependent pathways in human tongue cancer SCC-4 cells. Oral Oncol. 2009;45(3):273–283. doi:10.1016/j.oraloncology.2008.05.01218674953
   PubMed Web of Science ®Google Scholar
• Lu KW, Chen JC, Lai TY, et al. Gypenosides suppress growth of human oral cancer SAS cells in vitro and in a murine xenograft model: the role of apoptosis mediated by caspase-dependent and caspase-independent pathways. Integr Cancer Ther. 2012;11(2):129–140. doi:10.1177/153473541140330621665877
   PubMed Web of Science ®Google Scholar
• Wang QF, Chiang CW, Wu CC, et al. Gypenosides induce apoptosis in human hepatoma Huh-7 cells through a calcium/reactive oxygen species-dependent mitochondrial pathway. Planta Med. 2007;73(6):535–544. doi:10.1055/s-2007-96720017520521
   PubMed Web of Science ®Google Scholar
• Wu CC, Bratton SB. Regulation of the intrinsic apoptosis pathway by reactive oxygen species. Antioxid Redox Signal. 2013;19(6):546–558. doi:10.1089/ars.2012.490522978471
   PubMed Web of Science ®Google Scholar
• Reed JC. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ. 2006;13(8):1378–1386. doi:10.1038/sj.cdd.440197516729025
   PubMed Web of Science ®Google Scholar
• Letai A. BCL-2: found bound and drugged! Trends Mol Med. 2005;11(10):442–444. doi:10.1016/j.molmed.2005.08.00716150641
   PubMed Web of Science ®Google Scholar
• Kim H, Rafiuddin-Shah M, Tu HC, et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol. 2006;8(12):1348–1358. doi:10.1038/ncb149917115033
   PubMed Web of Science ®Google Scholar
• Green DR. At the gates of death. Cancer Cell. 2006;9(5):328–330. doi:10.1016/j.ccr.2006.05.00416697952
   PubMed Web of Science ®Google Scholar
• Zhu MY, Chen F, Niyazi M, Sui S, Gao DM. Variation in apoptotic gene expression in cervical cancer through oligonucleotide microarray profiling. J Low Genit Tract Dis. 2015;19(1):46–54. doi:10.1097/LGT.000000000000003024914885
   PubMed Web of Science ®Google Scholar
• Chen JC, Lu KW, Lee JH, Yeh CC, Chung JG. Gypenosides induced apoptosis in human colon cancer cells through the mitochondria-dependent pathways and activation of caspase-3. Anticancer Res. 2006;26(6b):4313–4326.17201150
   PubMed Web of Science ®Google Scholar
• Liu JS, Chiang TH, Wang JS, et al. Induction of p53-independent growth inhibition in lung carcinoma cell A549 by gypenosides. J Cell Mol Med. 2015;19(7):1697–1709. doi:10.1111/jcmm.1265825781909
   PubMed Web of Science ®Google Scholar
• Lu HF, Chen YS, Yang JS, et al. Gypenosides induced G0/G1 arrest via inhibition of cyclin E and induction of apoptosis via activation of caspases-3 and −9 in human lung cancer A-549 cells. In Vivo. 2008;22(2):215–221.18468406
   PubMed Web of Science ®Google Scholar
• Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104(4):487–501. doi:10.1016/S0092-8674(01)00237-911239407
   PubMed Web of Science ®Google Scholar
• Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008;19(3–4):325–331. doi:10.1016/j.cytogfr.2008.04.00118495520
   PubMed Web of Science ®Google Scholar
• Fulda S. Targeting extrinsic apoptosis in cancer: challenges and opportunities. Semin Cell Dev Biol. 2015;39:20–25. doi:10.1016/j.semcdb.2015.01.00625617598
   PubMed Web of Science ®Google Scholar
• Schroder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem. 2005;74:739–789. doi:10.1146/annurev.biochem.73.011303.07413415952902
   PubMed Web of Science ®Google Scholar
• Schroder M. Endoplasmic reticulum stress responses. Cell Mol Life Sci. 2008;65(6):862–894. doi:10.1007/s00018-008-7565-918038217
   PubMed Web of Science ®Google Scholar
• Oyadomari S, Araki E, Mori M. Endoplasmic reticulum stress-mediated apoptosis in pancreatic beta-cells. Apoptosis. 2002;7(4):335–345. doi:10.1023/A:101617542987712101393
   PubMed Web of Science ®Google Scholar
• Khan M, Rasul A, Yi F, Zhong L, Ma T. Jaceosidin induces p53-dependent G2/M phase arrest in U87 glioblastoma cells. Asian Pac J Cancer Prev. 2011;12(12):3235–3238.22471459
   PubMedGoogle Scholar
• Lu MC, Yang SH, Hwang SL, et al. Induction of G2/M phase arrest by squamocin in chronic myeloid leukemia (K562) cells. Life Sci. 2006;78(20):2378–2383. doi:10.1016/j.lfs.2005.09.04816310807
   PubMed Web of Science ®Google Scholar
• Yang G, Chang B, Yang F, et al. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res. 2010;16(12):3171–3181. doi:10.1158/1078-0432.CCR-10-061320423983
   PubMed Web of Science ®Google Scholar
• Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene. 2007;26(9):1306–1316. doi:10.1038/sj.onc.121026317322916
   PubMed Web of Science ®Google Scholar
• Bourougaa K, Naski N, Boularan C, et al. Endoplasmic reticulum stress induces G2 cell-cycle arrest via mRNA translation of the p53 isoform p53/47. Mol Cell. 2010;38(1):78–88. doi:10.1016/j.molcel.2010.01.04120385091
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–310. doi:10.1038/3504267511099028
   PubMed Web of Science ®Google Scholar
• Khan M, Zheng B, Yi F, et al. Pseudolaric Acid B induces caspase-dependent and caspase-independent apoptosis in u87 glioblastoma cells. Evid Based Complement Alternat Med. 2012;2012:957568. doi:10.1155/2012/95756822778780
   PubMed Web of Science ®Google Scholar
• Chen MH, Chen SH, Wang QF, et al. The molecular mechanism of gypenosides-induced G1 growth arrest of rat hepatic stellate cells. J Ethnopharmacol. 2008;117(2):309–317. doi:10.1016/j.jep.2008.02.00918372131
   PubMed Web of Science ®Google Scholar
• Furgason JM, Bahassi EM. Targeting DNA repair mechanisms in cancer. Pharmacol Ther. 2013;137(3):298–308. doi:10.1016/j.pharmthera.2012.10.00923107892
   PubMed Web of Science ®Google Scholar
• Lu KW, Chen JC, Lai TY, et al. Gypenosides causes DNA damage and inhibits expression of DNA repair genes of human oral cancer SAS cells. In Vivo. 2010;24(3):287–291.20555000
   PubMed Web of Science ®Google Scholar
• Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075–1083. doi:10.1200/JCO.2009.25.364120085938
   PubMed Web of Science ®Google Scholar
• Steelman LS, Chappell WH, Abrams SL, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany, NY). 2011;3(3):192–222. doi:10.18632/aging.10029621422497
   PubMedGoogle Scholar
• Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2010;20(1):87–90. doi:10.1016/j.gde.2009.11.00220006486
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554. doi:10.1126/science.109650215016963
   PubMed Web of Science ®Google Scholar
• Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3(10):1221–1224. doi:10.4161/cc.3.10.116415467468
   PubMed Web of Science ®Google Scholar
• Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2006;103(5):1289–1294. doi:10.1073/pnas.051077210316432180
   PubMed Web of Science ®Google Scholar
• Vincent EE, Elder DJ, Thomas EC, et al. Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer. 2011;104(11):1755–1761. doi:10.1038/bjc.2011.13221505451
   PubMed Web of Science ®Google Scholar
• Lu KW, Tsai ML, Chen JC, et al. Gypenosides inhibited invasion and migration of human tongue cancer SCC4 cells through down-regulation of NFkappaB and matrix metalloproteinase-9. Anticancer Res. 2008;28(2a):1093–1099.18507059
   PubMed Web of Science ®Google Scholar
• Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986;46(5):705–716. doi:10.1016/0092-8674(86)90346-63091258
   PubMed Web of Science ®Google Scholar
• Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007;8(1):49–62. doi:10.1038/nrm208317183360
   PubMed Web of Science ®Google Scholar
• Arkan MC, Greten FR. IKK- and NF-kappaB-mediated functions in carcinogenesis. Curr Top Microbiol Immunol. 2011;349:159–169.20845109
   PubMed Web of Science ®Google Scholar
• Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25(51):6817–6830. doi:10.1038/sj.onc.120994217072330
   PubMed Web of Science ®Google Scholar
• Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem. 2010;336(1–2):25–37. doi:10.1007/s11010-009-0267-219823771
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Arakawa T, Ueda N, Yamamoto S. Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem. 1995;270(52):31315–31320. doi:10.1074/jbc.270.52.313158537402
   PubMed Web of Science ®Google Scholar
• Park JH, Jeong YJ, Won HK, Choi SY, Park JH, Oh SM. Activation of TOPK by lipopolysaccharide promotes induction of inducible nitric oxide synthase through NF-kappaB activity in leukemia cells. Cell Signal. 2014;26(5):849–856. doi:10.1016/j.cellsig.2014.01.00424440499
   PubMed Web of Science ®Google Scholar
• Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103–119. doi:10.1517/14728222.2011.64580522239440
   PubMed Web of Science ®Google Scholar
• Chang F, Steelman LS, Lee JT, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003;17(7):1263–1293. doi:10.1038/sj.leu.240263712835716
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Abrams SL, et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia. 2008;22(4):708–722. doi:10.1038/sj.leu.240488918337766
   PubMed Web of Science ®Google Scholar
• Martelli AM, Evangelisti C, Chiarini F, et al. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta. 2010;1803(9):991–1002. doi:10.1016/j.bbamcr.2010.04.00520399811
   PubMed Web of Science ®Google Scholar
• Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. 2010;1(2):89–103.20671809
   PubMedGoogle Scholar
• Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014;13(12):928–942. doi:10.1038/nrd428125435214
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–3290. doi:10.1038/sj.onc.121042117496922
   PubMed Web of Science ®Google Scholar